Tradestie Institutional Equity Comparison Engine
CING vs DRMA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CING Overall Edge
CING Captures Institutional Edge (3โ0 Pillars ยท 5โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cingulate Inc. Common Stock (CING) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CING trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus DRMA at N/M Forward P/E and -13082.3% operating margin (+0.0% YoY). In options structure, CING sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro) against DRMA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CING N/M vs DRMA N/M Fwd P/E
Growth & Margin Winner
CING
Op Margin 0.0% vs -13082.3% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
CING
1Y +36.4% vs -81.1% ยท 52W Pos 18% vs 0%
Options & Structure Winner
CING
BREAKDOWN (16th %ile IV) vs UNCLASSIFIED (N/A IV)
CING
NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.76
+26.93% 1D
Market Cap
$62.5M
1M Return
+9.17%
1Y Return
+36.39%
Forward P/E
N/M
Unified AI Score
44.8 / 100
HOLD
Tech 31.0
Fund 50.0
Flow 67.0
Mom 60.0
DRMA
NASDAQ
Dermata Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.58
-3.14% 1D
Market Cap
$3.1M
1M Return
-32.59%
1Y Return
-81.12%
Forward P/E
N/M
Unified AI Score
43.8 / 100
HOLD
Tech 33.0
Fund 46.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CING +36.39%
DRMA -81.12%
Spread: +117.51 pp (CING Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CING TTM Op. Margin: 0.0%
DRMA TTM Op. Margin: -13082.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs DRMA. Trailing 12-month operating profitability (CING 0.0% vs DRMA -13082.3%) and valuation multiples (CING N/M vs DRMA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CING | DRMA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $62.5M | $3.1M | Larger Scale | CING |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | -13082.3% | Higher Margin | CING |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -198.7% | -241.5% | Higher ROE | CING |
| 52-Week Range Position Momentum | 18% ($3โ$12) | 0% ($1โ$5) | Stronger Trend | CING |
| Beta / 30D Volatility Risk Regime | 1.13ฮฒ ยท 117% Vol | 1.10ฮฒ ยท 112% Vol | Lower Realized Risk | DRMA |
| Unified Institutional Score Composite Signal | 44.8 / 100 (HOLD) | 43.8 / 100 (HOLD) | Higher Composite | CING |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CING vs DRMA Buy Guide
CING
BREAKDOWN
170d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
16th %ile
IV Regime
Compressed (<25th %ile)
DRMA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CING nor DRMA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.